Antitubercular fixed-dose combination (4FDC)
Rifampicin with ethambutol, isoniazid and pyrazinamide
Brand names: Voractiv
Adult dose
Dose: Weight-based: 30–37kg = 2 tabs OD; 38–54kg = 3; 55–70kg = 4; >70kg = 5 tabs PO OD for 2 months
Route: PO
Frequency: OD (intensive phase)
Clinical pearls
- Active TB intensive phase per WHO/NICE — switch to RH FDC at 2 months
- Co-prescribe pyridoxine 10mg/day to prevent isoniazid neuropathy
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Optic neuritis (ethambutol)
Side effects
- Hepatotoxicity
- Optic neuritis
- Peripheral neuropathy
- Hyperuricaemia
- Orange body fluids
- Drug interactions
Interactions
- Strong enzyme inducer (rifampicin)
- Many — see BNF Appendix 1
Monitoring
- LFTs
- Vision
- FBC
- Renal function
- Weight
Reference: BNF; NICE NG33; WHO; https://bnf.nice.org.uk/drugs/rifampicin-with-ethambutol-isoniazid-and-pyrazinamide/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023